Clinical Report: Withdrawal of Study on Triglyceride-Glucose Index

Overview

The article evaluating the triglyceride-glucose index for cardiovascular disease prediction has been retracted due to originality concerns. An investigation revealed significant similarities with previously published work, leading to the decision to retract the study.

Background

The triglyceride-glucose (TyG) index is considered a potential biomarker for cardiovascular disease risk, particularly in individuals with cardiovascular-kidney-metabolic syndrome. Accurate predictive metrics are crucial for effective risk stratification and management of cardiovascular conditions.

Data Highlights

No numerical or trial data is presented due to the retraction of the study.

Key Findings

• The original study was retracted due to concerns over originality and similarity to another published article.
• The investigation confirmed the validity of the complaint regarding the article's figures and tables.
• The authors of the retracted study cooperated with the investigation and agreed to the retraction.
• The retraction was approved by the editorial leadership of Frontiers of Endocrinology.
• Concerns were raised by external parties, including users on PubPeer, leading to the investigation.

Clinical Implications

The retraction of this study highlights the necessity for rigorous standards in research publication.

Conclusion

The retraction of the study emphasizes the need for integrity in research publication.

Related Resources & Content

1. Frontiers Editorial Office, Frontiers in Endocrinology, 2026 -- Retraction: Comparison of triglyceride-glucose index and triglyceride-glucose related indexes in predicting cardiovascular disease incidence among populations with cardiovascular-kidney-metabolic syndrome stages 0-3
2. Hong, J., Zhang, R., Tang, H. et al., Cardiovasc Diabetol, 2025 -- Comparison of triglyceride glucose index and modified triglyceride glucose indices in predicting cardiovascular diseases incidence among populations with cardiovascular-kidney-metabolic syndrome stages 0–3
3. Frontiers in Endocrinology — Triglyceride-glucose index and subclinical left ventricular dysfunction across cardiovascular-kidney-metabolic syndrome stages: a 7-year retrospective cohort study
4. Frontiers in Endocrinology — Impact of the longitudinal evolution of impaired fasting glucose on cardio-kidney-metabolic multimorbidity
5. Clinical Research in Cardiology — Linking the C-reactive protein-triglyceride glucose index (CTI) to cardiovascular and overall mortality risk in older adults: findings from three datasets
6. The Journal of Clinical Endocrinology & Metabolism — Association of Urinary Tricarboxylic Acid Cycle Metabolites with End-stage Kidney Disease Risk in Type 2 Diabetes Patients
7. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
8. Triglyceride-glucose-related indices and risk of cardiovascular disease and mortality in individuals with cardiovascular–kidney–metabolic (CKM) syndrome stages 0–3: a prospective cohort study of 282,920 participants in the UK Biobank | Cardiovascular Diabetology | Springer Nature Link